German Federal Regulator Confirms Additional Benefit of eribulin for Metastatic or Locally Advanced Breast Cancer
Frankfurt And Hatfield, England (ots/PRNewswire) - ? The German Federal Joint Committee (G-BA), the supreme decision-making body of the self-governing medical system in Germany, announced that it considers the use of Halaven(R) (eribulin) to have additional benefit versus comparative treatments, defined by the G-BA ...
mehr